Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
7(77.8%)
Phase 3
2(22.2%)
9Total
Phase 2(7)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT06668558Phase 2Recruiting

Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

Role: lead

NCT07075016Phase 3Recruiting

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

Role: collaborator

NCT04687098Phase 2Completed

Risk-adapted Therapy for Primary Acute Myeloid Leukemia

Role: lead

NCT00766779Phase 3Terminated

HCT Versus CT in Elderly AML

Role: collaborator

NCT01698879Phase 2Completed

Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment

Role: lead

NCT04602273Unknown

Treatment of High Risk Myelodysplastic Syndromes (MDS) Not Candidates for Allogeneic Transplantation of Hematopoietic Progenitors (ALO-HSCT)

Role: lead

NCT01700413Phase 2Completed

Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia

Role: lead

NCT01193400Phase 2Terminated

Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years

Role: collaborator

NCT01723657Phase 2Completed

Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)

Role: lead

NCT01716793Phase 2Completed

Risk-adapted Therapy for Adult Acute Myeloid Leukemia.

Role: lead

All 10 trials loaded